InsideArbitrage Event Driven Monitor – December 14, 2023
Merger Arbitrage
- RAIN: The acquisition of Rain Oncology by Pathos AI. Under the terms of the agreement, Pathos AI will acquire Rain for $1.16 in cash per share plus a non-tradeable contingent value right for potential cash payments of up to approximately $0.17 per share.
- AAIC: Arlington Asset Investment (AAIC) announced that its shareholders have voted to approve the proposed merger transaction with Ellington Financial (EFC). The Merger is expected to close on December 14, 2023.
- MRTX: Mirati Therapeutics (MRTX) shareholders approved the company’s merger with Bristol-Myers Squibb Company (BMY).
You can check out new deals, all deal updates, and spreads on active deals in our Merger Arbitrage Tool for premium members here.
Only plus or premium subscribers can access this post. Subscribe today.
